Slide 1: Preliminary Results for the Year Ending December 31st, 2023 and Business Update
Preliminary Results for the Year Ending December 31st, 2023 and Business Update 30th April 2024 © Avacta Group plc 2024
Slide 2: Disclaimer
Disclaimer For the purposes of this disclaimer, this “presentation” shall mean and include the slides that follow, the oral presentation of the slides by Avacta Group plc (the “Company”) or any person on its behalf, any question-and-answer session that follows the oral presentation, hard copies (inc
Slide 3: Avacta Appoints Christina Coughlin, MD, PhD as CEO
Avacta Appoints Christina Coughlin, MD, PhD as CEO “I am confident that Chris is the right person to lead Avacta’s next chapter. Her deep understanding of drug development and the urgent unmet needs in oncology, her extensive scientific and clinical experience and her many years in leadership roles
Slide 4: Leadership Team
Leadership Team Christina Coughlin, MD, PhD Tony Gardiner CEO CFO • Over 18 years’ experience of oncology • Over 25 years’ senior financial and drug development in both biotech and operational experience across multiple large pharmaceutical companies sectors • Former CEO of CytoImmune • Joined Avact
Slide 5: Avacta Group plc Preliminary Results for the Year Ending December 31st, 2023
Avacta Group plc Preliminary Results for the Year Ending December 31st, 2023 5 © Avacta Group plc 2024
Slide 6: Preliminary Results for Year Ending 31st December 2023 Income Statement
Preliminary Results for Year Ending 31st December 2023 FY23 vs FY22 2023 (£m) 2022 (£m) (£m) Income Statement Revenue 23.3 9.7 +13.6 • Launch Dx acquired October 2022; Coris BioConcept acquired June 2023. Gross profit 11.2 7.2 +4.0 • Increased gross profit from Dx of Research costs (14.5) (11.1) (3.
Slide 7: Operating Segment Analysis
Preliminary Results for the Period Ending 31st December 2023 Operating Segment Analysis 2023 (£m) 2022 (£m) Tx Dx Central Total Tx Dx Central Total Revenue 2.06 21.19 - 23.25 5.48 4.17 - 9.65 Gross profit 2.04 9.20 - 11.24 5.35 1.89 - 7.24 Research costs (13.11) (1.42) - (14.53) (8.79) (2.31) - (11.
Slide 8: Cash Flow
Preliminary Results for the Year Ending 31st December 2023 Cash Flow • Investing activities - relates to the 2023 (£m) 2022 (£m) Coris acquisition (£6.9m), deferred Cash/short term deposits at 1 41.78 26.19 acquisition payment re Launch tax January receipt (£0.9m) and capex (£1.1m). Operating cash o
Slide 9: Balance Sheet
Preliminary Results for the Year Ending 31st December 2023 Balance Sheet 2023 (£m) 2022 (£m) • Non-current assets include PPE, IFRS16 leases re Non-current assets 45.16 37.37 Avacta facilities, goodwill on the Launch and Coris acquisitions and investment in AffyXell. Current assets (exc. cash/deposi
Slide 10: Business Update
Business Update 10 © Avacta Group plc 2024
Slide 11: The Avacta Therapeutics Research and Development Team
The Avacta Therapeutics Research and Development Team Christina Coughlin, Simon Bennett, Karen Harrison, David Jones, Francis Wilson, MD, PhD DPhil MBA DPhil DPhil Chief Executive Officer Chief Business Officer Chief Operating Officer VP and Head of Biology VP and Head of Chemistry and Head of R&D D
Slide 12: Targeting Highly Toxic Warheads to the TME by Leveraging Tumor-Selective FAP Expression
Avacta is Targeting Highly Toxic Warheads to the TME by Leveraging Tumor-Selective FAP Expression Tumor antigen- pre|CISIONTM Fc region specific mAb peptide or Affimer warhead pre|CISION+ pre|CISION+ warheads warheads pre|CISION pre|CISION + pre|CISION ADC peptide drug Half-life optimized antibody/A
Slide 13: PDC and Affimer-DC Have Key Advantages Over Traditional ADC Approaches
PDC and Affimer-DC Have Key Advantages Over Traditional ADC Approaches PDC AffDC ADC Avacta v. Avacta v. Traditional Peptide Drug Conjugate Affimer Drug Conjugate Antibody Drug Conjugate Warhead released intracellularly Mechanism Extracellular warhead release with limited systemic exposure after int
Slide 14: AVA6000 Phase 1: Interim Clinical and PK/PD Results
AVA6000 PHASE 1: INTERIM CLINICAL AND PK/PD RESULTS 14 © Avacta Group plc 2024
Slide 15: AVA6000
AVA6000 p 15 © Avacta Group plc 2023 (CONFIDENTIAL) 15 © Avacta Group plc 2024
Slide 16: Key Findings in Phase 1
KEY FINDINGS IN PHASE 1 AVA6000 delivers high concentrations of doxorubicin to the TME relative to plasma, resulting in significant antitumor activity in patients whose tumours have over-expression of FAP PK/PD modeling suggests that released doxorubicin is generated primarily by cleavage in the TME
Slide 17: The AVA6000 Phase 1 Trial is Ongoing with Q2W Dosing Based on Low Toxicity
The AVA6000 Phase 1 Trial is Ongoing with Q2W Dosing Based on Low Toxicity PHASE 1: ARM 1 Q3W iv* 80 [54] 120 [81] 160 [108] 200 [135] 250 [169] 310 [209] 385 [260] [dox equivalent] N=4 N=6 N=8 N=7 N=9 N=4 N=4 Cohorts included in the (mg/m2) AACR data analysis low/standard dose doxorubicin escalated
Slide 18: AVA6000 Reduces Severe Toxicities and Improves the Quality of Life for Patients
AVA6000 Reduces Severe Toxicities and Improves the Quality of Life for Patients Observations compared with standard dose What are the implications of this improvement in (75 mg/m2) doxorubicin safety and tolerability? Observation One: It is possible to consider higher and/or more frequent A signific
Slide 19: First AVA6000 Responder Demonstrates Ongoing Dramatic Tumour Reduction
First AVA6000 Responder Demonstrates Ongoing Dramatic Tumour Reduction Case Study: 60-year-old male patient with a right-side popliteal mass biopsy diagnosed with a grade 3 Near undifferentiated pleomorphic complete sarcoma (UPS). Prior cancer therapy radiotherapy (May-Jul resolution 2021) followed
Slide 20: AVA6000 Leads to Tumour Responses in Patients with FAPhigh Indications
AVA6000 Leads to Tumour Responses in Patients with FAPhigh Indications 100 Many patients with FAPhigh indications have 80 evidence of tumor reduction including the 5 responders Four of the 5 responders are ongoing 60 Best percentage change in the sum of the longest diameters 40 20 0 * * * * * * -20
Slide 21: Robust Warhead Concentration in the TME Due to Tumour-Specific Cleavage
Robust Warhead Concentration in the TME Due to Tumour-Specific Cleavage 10000 Pts with FAPhigh Pts with FAPmid Log Doxorubicin concentration 1000 (ng/gm or ng/ml) Two-log difference between tumour and plasma concentration 100 10 1 FAPhigh indications were categorized by FAP expression in literature
Slide 22: pre|CISION: A Highly Precise Tumor Targeting Mechanism of Action
pre|CISION™ : A Highly Precise Tumor Targeting Mechanism of Action 1 2 3 4 Data show that the AVA6000 has Preliminary signs of Optimizing dose and pre|CISION™ improved the safety AVA6000 clinical schedule should platform works as and tolerability of activity are increase efficacy of designed doxorub
Slide 23: Diagnostics Division Update
Diagnostics Division Update Supporting healthcare professionals and improving access to high quality diagnostics Centralised Testing Decentralised Testing Distributor of medical diagnostics Developer of rapid tests Active in UK, France, Ireland, Belgium. Planned Germany. Active in 90+ countries thro
Slide 24: Summary
Summary • Avacta’s pre|CISIONTM platform is a highly tumour-specific drug release mechanism capable of concentrating anti-cancer drugs to the tumour microenvironment v. the plasma and can be leveraged in different formats • Our clinical data released at AACR provide clinical proof of concept for AVA
Slide 25: Avacta: Upcoming Milestones and Catalysts in 2H 2024
Avacta: Upcoming Milestones and Catalysts in 2H 2024 Initiate Expansion Updated AVA6000 Release Pipeline Cohorts Clinica Data Update Completing the Phase Updating the AVA6000 Release of the 1 dose escalation and clinical data to support updated pipeline of advancing the the next stage of Avacta Tx a
Slide 26: www.avacta.com
www.avacta.com © Avacta’ 26
Slide 27: Glossary
Glossary FAP – Fibroblast activation protein Topoisomerases - enzymes that play essential roles in DNA TME – Tumour micro environnent replication PREP – Prolyl endopeptidase – a protein coding gene Neutropenia - a low number of white blood cells called HEK– Human embryonic kidney neutrophils in the